A retrospective, single-center study of efficacy and safety of guselkumab, risankizumab and tildrakizumab in elderly patients with plaque psoriasis
Latest Information Update: 22 Mar 2022
At a glance
- Drugs Guselkumab (Primary) ; Risankizumab (Primary) ; Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 22 Mar 2022 New trial record
- 01 Mar 2022 Results published in the Clinical and Experimental Dermatology